<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21179" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Eosinophilia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kanuru</surname>
            <given-names>Sruthi</given-names>
          </name>
          <aff>Central Arkansas Veterans Healthcare System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sapra</surname>
            <given-names>Amit</given-names>
          </name>
          <aff>Southern Illinois University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sruthi Kanuru declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amit Sapra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21179.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Eosinophils are a kind of blood granulocytes that express cytoplasmic granules that contain basic proteins and bind with acidic dyes like &#x0201c;eosin.&#x0201d; They derive from bone marrow, and their production is stimulated by IL-5, IL-3, and GM-CSF. They have a circulating half-life of 4.5 to 8 hours. They can reside in tissues, mostly in the respiratory tract, and gastrointestinal tract, for 8 to 12 days. Eosinophils are less than 5% of circulating leukocytes. Eosinophilia is defined as an increase of circulating eosinophils &#x0003e;500 /mm^3. Based on the counts, eosinophilia can be divided into different categories: mild (500 to 1500/mm^3), moderate (1500 to 5000/mm^3), and severe (&#x0003e; 5000/mm^3). Hypereosinophilic syndrome is defined as an absolute eosinophil count greater than 1500/mm^3 on two occasions at least one month apart or marked tissue eosinophilia. This activity reviews the evaluation and treatment of eosinophilia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the possible etiologies for developing eosinophilia.</p></list-item><list-item><p>Review the steps in the evaluation of eosinophilia.</p></list-item><list-item><p>Summarize management options available for eosinophilia based on specific etiology.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21179&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21179">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21179.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Eosinophils are a kind of blood granulocytes that express cytoplasmic granules that contain basic proteins and bind with acidic dyes like &#x0201c;eosin.&#x0201d; They derive from bone marrow, and IL-5, IL-3, and GM-CSF stimulate their production.<xref ref-type="bibr" rid="article-21179.r1">[1]</xref>&#x000a0;They have a circulating half-life of 4.5 to 8 hours. They can reside in tissues, mostly in the respiratory tract and gastrointestinal tract, for 8&#x000a0;to 12 days. Eosinophils are less than 5% of circulating leukocytes. Eosinophilia is defined as an increase of circulating eosinophils &#x0003e;500 /mm^3.<xref ref-type="bibr" rid="article-21179.r1">[1]</xref>&#x000a0;</p>
        <p>Based on the counts, eosinophilia can subdivide into different categories: mild (500&#x000a0;and 1500/mm^3), moderate (1500 to 5000/mm3), and severe (&#x0003e; 5000/mm^3). Hypereosinophilic syndrome is defined as an absolute eosinophil count greater than 1500/mm3 on two occasions at least one month apart or marked tissue eosinophilia.<xref ref-type="bibr" rid="article-21179.r2">[2]</xref></p>
      </sec>
      <sec id="article-21179.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Eosinophilia can be primary or secondary<xref ref-type="bibr" rid="article-21179.r3">[3]</xref>:</p>
        <p>Primary causes <xref ref-type="bibr" rid="article-21179.r2">[2]</xref><xref ref-type="bibr" rid="article-21179.r4">[4]</xref><xref ref-type="bibr" rid="article-21179.r2">[2]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic eosinophilic leukemia</p>
          </list-item>
          <list-item>
            <p>Myeloid and lymphoid neoplasms with <italic toggle="yes">rearrangements of PDGFRA, PDGFRAB, or FGFR1</italic>&#x000a0;genes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hereditary eosinophilia</p>
          </list-item>
          <list-item>
            <p>Idiopathic hypereosinophilic syndrome</p>
          </list-item>
        </list>
        <p>Secondary causes <xref ref-type="bibr" rid="article-21179.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Parasitic infestations: ancylostomiasis, ascariasis, cysticercosis, echinococcosis (hydatid cyst), schistosomiasis, strongyloidiasis, trichinellosis, visceral larva migrans (toxocariasis)</p>
          </list-item>
          <list-item>
            <p>Fungal and bacterial infections: bronchopulmonary aspergillosis, chronic tuberculosis (occasionally), coccidioidomycosis, disseminated histoplasmosis, scarlet fever</p>
          </list-item>
          <list-item>
            <p>Allergic disorders: bronchial asthma, hay fever, Stevens-Johnson syndrome, drug, and food allergic reactions, DRESS syndrome</p>
          </list-item>
          <list-item>
            <p>Skin diseases: Atopic dermatitis, eczema, pemphigus, <italic toggle="yes">Mycosis fungoides</italic>, Sezary syndrome</p>
          </list-item>
          <list-item>
            <p>Graft versus host reaction</p>
          </list-item>
          <list-item>
            <p>Connective tissue disease: Chrug-Strauss syndrome, eosinophilic myalgia syndrome</p>
          </list-item>
          <list-item>
            <p>Miscellaneous: reactive pulmonary eosinophilia, tropical eosinophilia, pancreatitis, eosinophilic gastroenteritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21179.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence and prevalence of eosinophilia are not well described. There is no sex predilection for eosinophilia. However, there can be geographical influences depending on&#x000a0;its cause. Parasitic infestations are more prevalent in tropical countries. Allergic disorders are commonplace in developed countries.<xref ref-type="bibr" rid="article-21179.r5">[5]</xref>&#x000a0;Idiopathic hypereosinophilia is diagnosed between 20 and 50 years of age, but extreme ages at both ends of the curve are also known to occur.</p>
      </sec>
      <sec id="article-21179.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Eosinophils become differentiated in bone marrow, and once they leave the marrow, they stop maturing further. They reside in tissues, mostly outside the vasculature. In eosinophil related disorders, eosinophils are recruited into the involved tissues. T helper-2 cells mediated immune responses, and IL-5 production induce eosinophilopoiesis and eosinophil activation. The major cytokine responsible for eosinophil production and activation is IL-5 [9,10]. After activation, eosinophils degranulate and release the cationic proteins into the tissues through which eosinophils perform their functions. These released proteins can be proteolytic enzymes, which can cause damage to the host wall as well. Eosinophil also releases cytokines, like IL-10 and IL-14, which aid in maintaining homeostasis and immunoregulation.<xref ref-type="bibr" rid="article-21179.r6">[6]</xref><xref ref-type="bibr" rid="article-21179.r7">[7]</xref></p>
      </sec>
      <sec id="article-21179.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>An eosinophil is around 12&#x000a0;to 17 &#x000b5;m in diameter and has a segmented nucleus. It has abundant cytoplasmic granules that contain proteolytic enzymes. Four major proteins comprise the granules: major basic protein (MBP1), eosinophilic cationic protein (ECP), eosinophil derived neurotoxin (EDN), and eosinophil peroxidase (EOP). They stain red-orange with Romanowsky stains.<xref ref-type="bibr" rid="article-21179.r4">[4]</xref></p>
      </sec>
      <sec id="article-21179.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Due to the heterogeneous manifestations of the disease and severity varying from mild to end-organ damage, comprehensive history taking and diligent physical examination is extremely important, and sometimes enough, for diagnosis.<xref ref-type="bibr" rid="article-21179.r4">[4]</xref>&#x000a0;Skin, pulmonary, and gastrointestinal organ systems are commonly involved. Constitutional symptoms like low-grade fevers, night sweats, fatigue, weight loss can occur in multiple conditions, including myeloproliferative and lymphoid neoplasms, Churg Strauss syndrome, DRESS syndrome.</p>
        <p>Skin rashes, pruritus can be seen in cutaneous T cell lymphoma, eczema. Dyspnea, cough, wheezing can be seen in multiple conditions, including bronchopulmonary aspergillosis, Loeffler's syndrome, hay fever, asthma, reactive pulmonary eosinophilia, Churg strass syndrome. Detailed travel history, work environment, drug history, close contacts with HIV, syphilis helps identify infections, parasitic infestations, and drug adverse reactions.<xref ref-type="bibr" rid="article-21179.r8">[8]</xref><xref ref-type="bibr" rid="article-21179.r9">[9]</xref>&#x000a0;Physical examination should be complete, including a skin assessment, lung auscultation to look for rhonchi, wheezes, abdomen exam to look for splenomegaly.</p>
      </sec>
      <sec id="article-21179.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Secondary causes of eosinophilia should be ruled out first. The evaluation for primary eosinophilia should begin with screening peripheral blood for FIP1L1- PDGFRA gene fusion. Diagnostic testing should start with peripheral smear. Cytogenetic testing and FISH analysis&#x000a0;can be performed on peripheral blood as well.<xref ref-type="bibr" rid="article-21179.r4">[4]</xref><xref ref-type="bibr" rid="article-21179.r8">[8]</xref></p>
        <p>Concurrent cytophilias or cytopenias, if present, can help with diagnosis. In that case, a bone marrow biopsy, along with karyotype and genetic screen of chromosomes, may be required.<xref ref-type="bibr" rid="article-21179.r5">[5]</xref><xref ref-type="bibr" rid="article-21179.r10">[10]</xref>&#x000a0;</p>
        <p>B12 level and tryptase level, along with cytogenetic/immunophenotypic testing and marrow findings, help diagnose chronic mastocytosis, acute/chronic myeloid leukemia, myelodysplastic syndrome, and MDS/MPN overlap. When skin rashes are present, skin biopsy helps to diagnose cutaneous disorders like pemphigoid, eczema, mycosis fungoides, and Sezary syndrome. Imaging of the chest helps diagnose aspergillosis, Loeffler syndrome, and Churg Strauss syndrome. Ultrasound abdomen helps to evaluate for splenomegaly. Stool testing helps to assess for parasitic infections.</p>
      </sec>
      <sec id="article-21179.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management depends on the underlying cause. The goal of the therapy is to mitigate end-organ damage from eosinophilia.<xref ref-type="bibr" rid="article-21179.r10">[10]</xref>&#x000a0;In mild cases without any symptoms or signs of organ involvement, a conservative approach can be undertaken. In emergency conditions with hemodynamic instability or organ failure, treatment with IV steroids is important.<xref ref-type="bibr" rid="article-21179.r8">[8]</xref>&#x000a0;</p>
        <p>For some conditions like drug and food allergies or infections, treatment can be simple, like withdrawing the offending agent or treating it with antibiotics. But in some conditions, due to the varying clinical manifestations and multi-systemic involvement, an interprofessional approach involving hematologists, pulmonologists, and infectious disease specialists, might be necessary. In steroid-resistant cases of hypereosinophilic syndrome and chronic eosinophilic leukemia, hydroxyurea and interferon-alpha have demonstrated efficacy.</p>
        <p>In aggressive forms of the disease, second-line cytotoxic agents and stem cell transplants have proven some benefits. Antibody use against interleukin-5 (IL-5) (mepolizumab), the IL-5 receptor (benralizumab), and CD52 (alemtuzumab), as well as other targets on eosinophils, continues to be an active area of investigation.<xref ref-type="bibr" rid="article-21179.r10">[10]</xref><xref ref-type="bibr" rid="article-21179.r9">[9]</xref>&#x000a0;Timely intervention is vital to reduce morbidity and mortality.</p>
      </sec>
      <sec id="article-21179.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Diagnoses can be narrowed down based on the predominant system involved. For example, when manifested with pulmonary symptoms: asthma, bronchopulmonary aspergillosis, with hay fever: skin involvement: <italic toggle="yes">Mycosis fungoides</italic>, Sezary syndrome, eczema, and bullous pemphigoid.</p>
      </sec>
      <sec id="article-21179.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis can be varying from mild disease to fatal outcome, depending on multiple factors like the cause of the eosinophilia, the presence of organ damage, the subtype of eosinophilia, and the timeline of intervention.</p>
      </sec>
      <sec id="article-21179.s12" sec-type="Complications">
        <title>Complications</title>
        <p>As eosinophils can produce proinflammatory cytokines and contain proteolytic enzymes that can damage the host cell wall, tissue damage can occur if not treated appropriately. Based on the etiology, the outcome can be fatal and cause severe end-organ damage.</p>
      </sec>
      <sec id="article-21179.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>When multiple symptoms are not explainable or when there is an exacerbation of an underlying condition without any risk factors, patients need to seek prompt medical attention. They need to give their physician a detailed history, including their living conditions, travel, and medications.</p>
      </sec>
      <sec id="article-21179.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>When there is no obvious cause found, pathologists should recommend further hematology testing like FISH analysis and cytogenetics. When there is a multi-systemic involvement, early intervention with an interprofessional approach helps.<xref ref-type="bibr" rid="article-21179.r8">[8]</xref></p>
      </sec>
      <sec id="article-21179.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21179&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21179">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/eosinophilia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21179">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21179/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21179">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21179.s16">
        <fig id="article-21179.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Coagulative Necrosis in Myocytes During Silent Myocardial Ischemia. Small foci of coagulative necrosis can be recognized on hematoxylin and eosin-stained sections: ischaemic myocytes typically show the hypereosinophilia that characterizes early phases of coagulative necrosis. (A) The ischemic myocytes are located on the left side of the panel; (B) the ischemic myocytes are positioned at the bottom left; (C) low magnification view showing a small area of acute myocardial infarction in which granulocyte infiltration is visible among the myocytes showing coagulative necrosis (squared area and (D), inset at higher magnification). The front of the myocardial ischemia is in the top half of the image. Pasotti M, Prati F,&#x000a0;Arbustini E. The pathology of myocardial infarction in the pre- and post-interventional era. <italic toggle="yes">Heart.</italic> 2006;92(11):1552-1556. doi: 10.1136/hrt.2005.086934.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ht86934_f1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-21179.s17">
        <fig id="article-21179.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Angiolymphoid Hyperplasia With Eosinophilia.&#x000a0;Angiolymphoid hyperplasia with eosinophilia, also known as epithelioid hemangioma, is an uncommon, benign vasoproliferative disorder. Contributed by B Lagha Imene</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PICT4526" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21179.s18">
        <title>References</title>
        <ref id="article-21179.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kovalszki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilia.</article-title>
            <source>Prim Care</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>607</fpage>
            <page-range>607-617</page-range>
            <pub-id pub-id-type="pmid">27866580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klion</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilia: a pragmatic approach to diagnosis and treatment.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>92</fpage>
            <page-range>92-7</page-range>
            <pub-id pub-id-type="pmid">26637706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magnaval</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gaudr&#x000e9;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fillaux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia.</article-title>
            <source>Mil Med Res</source>
            <year>2017</year>
            <volume>4</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">28546866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>How I investigate Eosinophilia.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-161</page-range>
            <pub-id pub-id-type="pmid">30499630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naymagon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marcellino</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilia in acute myeloid leukemia: Overlooked and underexamined.</article-title>
            <source>Blood Rev</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>36</volume>
            <fpage>23</fpage>
            <page-range>23-31</page-range>
            <pub-id pub-id-type="pmid">30948162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fulkerson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Eosinophil Development, Disease Involvement, and Therapeutic Suppression.</article-title>
            <source>Adv Immunol</source>
            <year>2018</year>
            <volume>138</volume>
            <fpage>1</fpage>
            <page-range>1-34</page-range>
            <pub-id pub-id-type="pmid">29731004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>The Eosinophil in Health and Disease: from Bench to Bedside and Back.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-39</page-range>
            <pub-id pub-id-type="pmid">26410377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butt</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Duncombe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ewing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Knapper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLornan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Radia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>BJ</given-names>
              </name>
              <collab>British Committee for Standards in Haematology</collab>
            </person-group>
            <article-title>Guideline for the investigation and management of eosinophilia.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>176</volume>
            <issue>4</issue>
            <fpage>553</fpage>
            <page-range>553-572</page-range>
            <pub-id pub-id-type="pmid">28112388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leiferman</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Eosinophil-Related Disease and the Skin.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>1462</fpage>
            <page-range>1462-1482.e6</page-range>
            <pub-id pub-id-type="pmid">29902530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21179.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gotlib</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>92</volume>
            <issue>11</issue>
            <fpage>1243</fpage>
            <page-range>1243-1259</page-range>
            <pub-id pub-id-type="pmid">29044676</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
